INNOVATE

Research within reach

From discovery-stage research to human clinical trials, the Fitzsimons Innovation Campus puts you within walking distance of everything you need to drive innovation, test and validate clinical science and maintain a commercial trajectory. This makes the District a great location for any company wishing to avoid the costs associated with building discovery-to-clinic infrastructure.

Denver medical research and bioscience research facilities and support

Since 1994, more than 140 companies based on CU research have spun off from CU’s four campuses. CU startups enjoy a higher survival rate than the average small business nationwide.

Thanks to the District’s adjacency to CU’s Anschutz Medical Campus and its formal affiliation with the University of Colorado that provides priority access, you’ll have a wide variety of facilities to support your research and product development. Click HERE to learn about everything that the Anschutz Medical Campus has to offer.

Anschutz Medical Campus Core Facilities & Services

The companies located on the Fitzsimons Innovation Campus are able to utilize the services of the university core labs located in the Research Complex buildings on the adjacent Anschutz Medical Campus.  These University Core Facilities provide equipment and expertise that may be too expensive for many companies to efficiently develop in their own laboratories.

The core labs also provide quality controls on certain activities or products routinely used in research, reduce the costs associated with various research activities, and promote technology transfer from laboratory research to patient care.  While these core labs must give top priority to university research, through the Fitzsimons Redevelopment Authority’s Affiliation Agreement, they offer services to the companies on the Fitzsimons Innovation Campus at a higher priority than other commercial entities.

The Core Facilities include:

  • Biophysics
  • Biostatistics and Bioinformatics
  • Computational Biology
  • Cytogenetics
  • DNA Sequencing & Analysis
  • Flow Cytometry
  • Laboratory Animals
  • PCR
  • Mass Spectrometry
  • Metabolic
  • Micro Array
  • Microscopy
  • NMR
  • Pathology
  • Pharmacokinetics & Modeling
  • Protein Expression, Monoclonal Antibody, Tissue Culture
  • Pharmacology Core
  • Proteomics Core
  • Transgenic/Knockout
  • X-Ray Cystallography

State of discovery

The Colorado research community is healthy and diverse — one that is characterized by a sophisticated entrepreneurial spirit and true cross-disciplinary collaboration. The research going on in Colorado is spread across a broad spectrum of drug targets and therapeutics, diagnostics, devices, research tools, biomaterials and drug delivery. And the intellectual capital amassed here is on par with other elite bioscience centers around the world. A few numbers help tell the story …

Bioscience in Colorado

(From CBSA website – http://www.cobioscience.com/resources/Bio-Science-in-Colorado-Fact-Sheet)

Colorado Statistics

  • Over 600 bioscience companies are located in Colorado including biotechnology, medical device, diagnostic, agricultural-biotech, and pharmaceutical companies.
  • Currently, Colorado employs 27,000 people in the bioscience industry, creating over 122,000 direct and indirect jobs, translating into over $10 billion in payroll.
  • Average annual wage is $84,000.
  • Total medical devices and diagnostics employment increased 8.9% between 2008 and 2013.
  • Total biotech and pharmaceutical direct employment increased 1.7% from  2012 to 2013.
  • Colorado research institutions collectively spin out 20 new bioscience companies each year on average.
  • Colorado’s medical device sector is the sixth-largest in the nation.
  • The State’s Bioscience Discovery Evaluation Grant Program has awarded 220 grants totaling more than $27 million, creating 45 new companies, 381 direct jobs, and  $418 million in follow-on grants and investments.
  • Venture capital investments in Colorado bioscience companies totaled $1.625 billion in the last five years with an additional $10.166 billion in acquisitions.
  • Colorado ranked fourth in the nation for funds raised per worker from the SBIR grant program and received more than $75.1 million in 2012.

Sources:

Toward a More Competitive Colorado, Annual Report – Metro Denver EDC

Battelle/Bio’s State Bioscience Industry Development 2012

Colorado State University contributions

There’s also Colorado State University (CSU), which has emerged as another powerful engine of innovation. In its most recent fiscal year, CSU reported 80 invention disclosures, 74 U.S. patent applications with four patents granted, 18 exclusive or non-exclusive options and licenses, and five start-up companies formed. CSU’s College of Veterinary Medicine and Biomedical Sciences is the perfect complement to the University of Colorado School of Medicine at the Anschutz Medical Campus. CSU’s main campus is located in Ft. Collins, which is also the location of the Centers for Disease and Control Division of Vector Borne Infectious Diseases.

Denver’s medical research at National Jewish Health

Another major player in Colorado’s bioscience research community is National Jewish Health in downtown Denver. US News and World Report has named National Jewish the #1 respiratory hospital in America for the last 12 years. But its contribution goes far beyond clinical excellence. Denver medical research at NJH has resulted in 110 active technologies protected by 79 active US patents, 170 exclusive and non-exclusive options and licenses, and 8 start-up companies.

A community without walls

Although impressive, these numbers hint at what may be an even more important story for any organization looking at Colorado as a potential location. Underlying all the patents, licenses and start-ups is the fact that Colorado’s bioscience community is just that — a community. It has been described as a community “without walls.” An environment where collaboration is seen as the most powerful catalyst for both discovery and commercial success.